Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ERYPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ERYPAR.
E.E.S. 200 vs ERYPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic